Monday July 16, 2018
Home India Shoulder-to-s...

Shoulder-to-shoulder: Donald Trump and Narendra Modi seal amiable relations with a telephonic conversation

0
//
156
America's new President Donald address a rally
Trump addressing a debate, wikimedia
Republish
Reprint

New Delhi, Jan 26, 2017: US President Donald Trump, over a phone call with Narendra Modi sealed the amiable relations between India and USA with a vow to stand “shoulder-to-shoulder” in the fight against terror and strengthen defence and economic ties.

The two leaders also extended invitations to each other for bilateral visits, over a phone call last night. The White House said in a statement, “During a call with Prime Minister Narendra Modi of India, President Trump emphasised that the US considers India a true friend and partner in addressing challenges around the world.”

NewsGram brings to you current foreign news from all over the world.

A US tour by Prime Minister Narendra Modi is also expected somewhere later in this year as White House gave a statement, “President Trump looked forward to hosting Prime Minister Modi in the US later this year.” Trump and Modi also discussed security in the region of South and Central Asia. Modi validated the strengthening relations between the two countries through a tweet which said, “Had a warm conversation with President @realDonaldTrump late last evening.”

NewsGram brings to you top news around the world today.

“Have also invited President Trump to visit India,” Modi said. Modi was among the first few world leaders who congratulated him after Trump’s historic victory on November 8. Seems like President Trump is keen on strengthening international ties as he had a conversation with the British Prime Minister Theresa May, Canadian Prime Minister Justin Trudeau and Mexican President Enrique Pena Nieto.

Check out NewsGram for latest international news updates.

On Sunday, Trump also spoke with Israeli Prime Minister Benjamin Netanyahu and on Monday he had a telephonic conversation with the Egyptian President Abdel Fattah el-Sisi.

– prepared by Shambhavi Sinha of NewsGram. Twitter:  @shambhavispeaks

Click here for reuse options!
Copyright 2017 NewsGram

Next Story

Cepheid to Establish Manufacturing Unit for TB Diagnostics in India

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment

0
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.
The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach. (IANS)

Expanding its footprint in India, US-based molecular diagnostics company Cepheid Inc on Thursday announced its plans to establish a manufacturing unit in the country to improve Tuberculosis (TB) diagnostics.

Cepheid’s GeneXpert MTB/RIF test is a closed-cartridge-based system that is easy to operate by minimally trained staff and gives results in approximately two hours, speeding the conventional backlog that used to exist in traditional diagnostic methods.

The new manufacturing unit would produce MTB/RIF test cartridges, contribute to the government’s “Make in India” initiative and thus bringing the company’s global expertise in TB diagnostics to India, the company said in a statement.

As part of the plan, Cepheid also unveiled its latest portable, easy-to-use TB-testing system — the GeneXpert Edge — which is expected to be available in India later this year, the company said.

The GeneXpert Edge is developed specifically for near-patient testing, to help support a one visit test-and-treat approach.

“Cepheid recognises the need for technological advancement and is committed to contributing significantly to India’s goal of TB eradication,” said Peter Farrell, Executive Vice President, Worldwide Commercial Operations, Cepheid.

Cepheid's Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB)
Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB).

“We are hopeful that GeneXpert Edge will help eliminate delays in TB diagnostics by providing definitive results within hours and facilitating fast and easy last-mile delivery even in the remote villages of India,” he added.

India has nearly one-fourth of the global TB patients and an estimated 4.8 lakh lives are lost every year due to delayed diagnosis and inadequate treatment and there are above 2.5 million new cases of TB every year. The country aims to eradicate TB by 2025.

Approved by the World Health Organisation (WHO) in 2010, more than 1,200 Cepheid’s GeneXpert Systems have been installed in the last two years at various Revised National Tuberculosis Control Programme (RNTCP) sites in the country and more than 2.5 million cartridges were supplied last year at various centres of Central TB Division (CTD).

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

Cepheid’s Xpert MTB/RIF test has the potential to detect Mycobacterium tuberculosis(MTB) and rifampicin-resistance mutations, which are markers for MDR-TB strains in under two hours.

Rifampicin is a drug commonly used in treating TB bacteria in first line of treatment.

Xpert MTB/RIF tests also have excellent negative predictive value, which allows clinicians to manage TB-negative patients more effectively to prevent unnecessary and costly respiratory isolations. (IANS)